Merle Diamond
Merle Diamond
The purpose of this study is to assess the efficacy of erenumab on functional impact due to Migraine in adults.
Migraine
Erenumab-Aooe 140 MG/ML [Aimovig]
PHASE4
This is a single group, multicenter, open-label study with a study population of patients who meet International Classification of Headache Disorders 3rd edition (ICHD-III) criteria for migraine with or without aura and have 4 to 20 migraine days per month. This is a single-group supportive care study with one arm and no masking. A maximum of 54 participants will be enrolled to study intervention. All participants in this single-group study will complete a 4-week run-in period. After the run-in period, eligible participants will be enrolled to study intervention and enter a 12-week treatment period.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 55 participants |
Masking : | NONE |
Primary Purpose : | SUPPORTIVE_CARE |
Official Title : | A Multicenter, Open Label Study Assessing the Efficacy of Erenumab on Functional Impact of Migraine |
Actual Study Start Date : | 2020-10-22 |
Estimated Primary Completion Date : | 2022-06-03 |
Estimated Study Completion Date : | 2022-06-03 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 65 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Diamond Headache Clinic
Chicago, Illinois, United States, 60642
Not yet recruiting
StudyMetrix
Saint Peters, Missouri, United States, 63303
Not yet recruiting
Clinvest Research
Springfield, Missouri, United States, 65810